Authors: Rodrigues, C.1; Jani, J.2; Shenai, S.1; Thakkar, P.1; Siddiqi, S.3; Mehta, A.1

Source: The International Journal of Tuberculosis and Lung Disease, Volume 12, Number 12, December 2008 , pp. 1449-1455(7)

Publisher: International Union Against Tuberculosis and Lung Disease

Abstract:

OBJECTIVE: To establish the critical test concentrations for seven second-line anti-tuberculosis drugs in the Bactec Mycobacterial Growth Indicator Tube (MGIT) 960 TB system and to evaluate its efficacy compared to the Bactec 460 TB system.

DESIGN: This study was carried out in three phases. In Phase I, pan-susceptible strains were tested to establish the minimum inhibitory concentration; in Phase II, mostly resistant strains were tested to determine a critical test concentration; and in Phase III, actual clinical isolates were tested to validate the optimal critical concentrations established in Phases I and II.

RESULTS: The critical concentrations established for seven second-line drugs with the Bactec MGIT 960 system are amikacin 1.0 μg/ml, capreomycin 2.5 μg/ml, kanamycin 2.5 μg/ml, ofloxacin 2.0 μg/ml, moxifloxacin 1.0 μg/ml, ethionamide 5.0 μg/ml and para-amino salicylic acid 4.0 μg/ml.

CONCLUSION: The Bactec MGIT 960 System is an accurate and reliable method for rapid drug susceptibility testing (DST) of Mycobacterium tuberculosis against second-line drugs. In the present study, few of the strains were resistant to fluoroquinolones and further DST for this group is required. 
Keywords: drug susceptibility testing; MGIT 960; India

Document Type: Regular paper

Affiliations: 1: Department of Microbiology, P D Hinduja National Hospital and Medical Research Centre Tertiary Care Hospital, Mumbai, India 2: Becton Dickinson Diagnostic Systems, Becton Dickinson, Mumbai, India 3: Becton Dickinson Diagnostic Systems, Sparks, Maryland, USA

Saiba mais em: http://www.ingentaconnect.com/content/iuatld/ijtld/2008/00000012/00000012/art00019

Sobre a REDE-TB

A Rede Brasileira de Pesquisa em Tuberculose (REDE-TB) é uma Organização Não Governamental (ONG) de direito privado sem fins lucrativos, preocupada em auxiliar no desenvolvimento não só de novos medicamentos, novas vacinas, novos testes diagnósticos e novas estratégias de controle de TB, mas também na validação dessas inovações tecnológicas, antes de sua comercialização no país e/ou de sua implementação nos Programa de Controle de TB no País.


bt2

Contato

E-mail: redetb.rp@gmail.com

Tel: +55 (21)3938 - 2426
Tel/ Fax: +55 (21)3938 - 2431.

Endereço: Avenida Carlos Chagas Filho, 791, Cidade Universitária - Ilha do Fundão, Rio de Janeiro, RJ - Brasil. CEP: 21941-904

Assine a newsletter da REDE-TB

Curta REDE-TB no Facebook